Drug Trial Radar · NCT05203692
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Feb 2, 2022
Primary completion
Jan 25, 2023
Study completion Mar 22, 2023
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Jan 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be the first-in-human study designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of DS-7011a in healthy participants.
Conditions
- Systemic Lupus Erythematosus
Interventions
DS-7011aDrug
Intravenous or subcutaneous administration, single dose
PlaceboDrug
Intravenous or subcutaneous administration, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events Following Administration with DS-7011a in Healthy ParticipantsTime frame: Screening (Day -28 to Day -7) up to Day 57 post-dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Apex Clinical Research (Collaborative Neuroscience Research)
Long Beach, California
Worldwide Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.